Daan Gene Co., Ltd.: history, ownership, mission, how it works & makes money

Born in 1988 as Guangdong Province Ke Si Da Medical Instrument Industry Company and transformed through affiliations with Zhongshan Medical University before listing on the Shenzhen Stock Exchange in 2004 under ticker 002030.SZ, Daan Gene Co., Ltd. today blends a legacy in diagnostics with modern molecular tools-qPCR, sequencing, TRF, ELISA and Liquid-Based Cytology-operating two core segments: Biological Products (reagents, instruments, consumables) and Financial Business (investments and asset management); the company reported a trailing twelve-month revenue of 765.48 million CNY in 2025, a year-over-year decline of 17.66%, and as of November 14, 2025 carried a market capitalization of 9.63 billion CNY with roughly 1.40 billion shares outstanding and Guangzhou Zhongda Holdings Co., Ltd. as the largest shareholder at 16.63%, while emphasizing R&D-driven high-sensitivity, high-specificity diagnostics and collaboration with hospitals and research institutions to commercialize clinical test reagents and expand its product portfolio

Daan Gene Co., Ltd. (002030.SZ): Intro

• 1988 - Established as Guangdong Province Ke Si Da Medical Instrument Industry Company, focused on medical diagnostics.
• 1992 - Renamed Zhongshan Medical University Technology Development Company, reflecting affiliation with Zhongshan Medical University.
• 1998 - Renamed Zhongshan Medical University Daan Gene Co., Ltd., emphasizing genetic diagnostics specialization.
• 2000 - Renamed Zhongshan University Daan Gene Co., Ltd., aligning with university rebranding.
• 2004 - Listed on the Shenzhen Stock Exchange (ticker: 002030.SZ).
• 2025 - Reported trailing twelve months (TTM) revenue of 765.48 million CNY, a decrease of 17.66% year‑over‑year.

• Listed public company structure with shares traded on Shenzhen Stock Exchange (002030.SZ).
• Origins and significant early ownership tied to Zhongshan Medical University / university-affiliated entities.
• Investor base typically includes institutional investors, strategic shareholders, and retail float (standard for A‑share biotech/diagnostics firms).
• Board and management combine academic founders/technicians and professional executives to manage commercialization and regulatory matters.

• Mission: develop and commercialize molecular diagnostics and genetic testing solutions to improve clinical decision-making and public health.
• Strategic focus areas: IVD reagents and instruments, molecular diagnostic kits (infectious disease, genetic disease, oncology), and expanding distribution channels domestically and regionally.
• Investment emphasis: product R&D, regulatory approvals, manufacturing scale‑up, and channel/distributor partnerships.

• R&D and product development: assay design, validation, clinical trials and regulatory submissions for in vitro diagnostic (IVD) kits and platforms.
• Manufacturing: GMP‑compliant production of reagent kits and consumables; scale-up to meet hospital and CDC demand.
• Sales & distribution: direct sales to hospitals, CDCs, third‑party laboratories and through agents/distributors across China and selected export markets.
• After‑sales and technical support: training, quality control, and service for lab instrumentation and assay use.

• Product sales: primary revenue from sale of diagnostic kits (molecular reagents), instruments and consumables.
• Service contracts: calibration, maintenance, technical training and assay validation services for institutional customers.
• OEM & distribution arrangements: manufacturing for third parties and revenue-sharing distribution partnerships.
• Licensing & collaborative R&D: fees or milestone payments from strategic partnerships with medical institutions or biotech companies.

• Pricing and procurement cycles in public hospitals and CDCs strongly affect revenue timing and order size.
• Product mix shifts (e.g., higher margin proprietary kits vs. lower margin OEM sales) drive gross margin variability.
• Regulatory approvals and evidence from clinical validation determine adoption speed in hospital labs.
• Competition from larger multinational IVD firms and fast‑moving domestic peers pressures pricing and market share.

Daan Gene Co., Ltd. (002030.SZ): History

• Founded: 1993
• Listing: Shenzhen Stock Exchange (002030.SZ)
• Core business evolution: PCR reagents → molecular diagnostics platforms → integrated testing solutions
• Geographic reach: Nationwide China distribution with targeted international exports

• Public listing: Shenzhen Stock Exchange, ticker 002030.SZ
• Market capitalization (as of 2025-11-14): 9.63 billion CNY
• Shares outstanding: ~1.40 billion
• Largest shareholder: Guangzhou Zhongda Holdings Co., Ltd. - 16.63% stake
• Other holders: mix of institutional investors and individual retail investors
• Management: experienced team with backgrounds in biotechnology, clinical diagnostics and business management

• Provide accurate, accessible molecular diagnostic solutions to improve public health and patient outcomes
• Advance biotechnology through R&D investment and platform development
• Support clinical decision-making with reliable testing products and services

• Product portfolio: PCR kits (infectious disease panels), oncology kits, prenatal/genetic screening kits, associated consumables
• Platform sales: diagnostic instruments and automated analyzers sold to hospitals, labs and third-party testing centers
• Consumable recurring revenue: high-margin reagent and kit sales that generate repeatable cash flows
• Testing services & partnerships: contracts with hospitals/third-party labs for outsourced testing and screening programs
• OEM and export sales: manufacturing for other brands and international distributors
• R&D-driven pipeline: new assays and platform upgrades to capture market share and command premium pricing

Daan Gene Co., Ltd. (002030.SZ): Ownership Structure

• Mission and values: advance molecular diagnostics to improve healthcare outcomes through innovation, quality and global-standard products.
• Core activities: R&D, manufacturing and service of in‑vitro diagnostic kits and instruments across qPCR, sequencing, TRF, ELISA and LBC.
• Strategic focus: early detection and management, collaborating with clinical and research partners to enhance diagnostic capabilities and healthcare efficiency.

• How it makes money: sales of diagnostic kits and instruments, reagent consumables, service & maintenance contracts, and OEM/partner sales to clinical labs and hospitals.
• Product mix: reagent kits (qPCR, sequencing, TRF, ELISA, LBC), diagnostic instruments (PCR machines, sequencers), consumables and ancillary services.

• R&D intensity supports ongoing product upgrades to meet international standards and expand indications (infectious disease panels, oncology markers, prenatal testing).
• Revenue drivers: recurring reagent sales (high-margin consumables), instrument placement (CAPEX cycles) and expanding service footprint in domestic and export markets.

Daan Gene Co., Ltd. (002030.SZ): Mission and Values

• Two operating segments: Biological Products and Related Business; Financial Business (investment and asset management).
• Biological Products: research, development, manufacturing, and sales of clinical test reagents, diagnostic instruments, and supporting consumables.
• Financial Business: strategic investments, equity holdings, and asset management to optimize capital allocation and returns.

• Core technologies: quantitative PCR (qPCR), real-time PCR platforms, and sequencing-based methods used across kit and instrument lines.
• Product pipeline: molecular diagnostic kits targeting infectious diseases, genetic screening, oncology markers, and companion diagnostics.
• Distribution and partnerships: products are distributed through collaborations with hospitals, third-party clinical laboratories, public health institutions, and research centers.

• Supply chain: centralized procurement of raw materials and reagents, with qualified domestic and international suppliers and quality-inspection controls to ensure batch-to-batch consistency.
• Manufacturing: vertically integrated production lines for reagent kit formulation, lyophilization, assembly of instruments, and packaging to maintain throughput and regulatory compliance.
• R&D investment: sustained R&D spending to expand product portfolio, accelerate regulatory approvals, and develop next-generation assays and automation.

• Primary revenue from sales of diagnostic reagents and instruments (high-margin consumables and recurring kit sales).
• Revenue diversification via service agreements, contract manufacturing, and technical support for institutional customers.
• Financial Business contributes non-operating income via investment returns, dividends, and asset management fees, smoothing earnings volatility.

• Strategic alliances with tertiary hospitals and provincial CDCs for clinical validation and large-scale product adoption.
• Distribution networks include direct sales teams, authorized distributors, and OEM/ODM partnerships for specific markets.
• Clinical support and training programs that increase adoption of instruments and ensure repeat reagent consumption.

• Investment portfolio includes minority stakes in biotech and diagnostics startups, plus cash management and fixed-income instruments.
• Asset management activities provide liquidity management and incremental income, particularly in periods of lower reagent demand.

Daan Gene Co., Ltd. (002030.SZ): How It Works

• Founded in the 1990s in Guangzhou, Daan Gene built its business around nucleic acid diagnostics and expanded into a broad portfolio of molecular diagnostic reagents, instruments and supporting consumables.
• Listed on the Shenzhen Stock Exchange (002030.SZ), the company has grown via product development, regional commercialization, and selective investments into related healthcare financial services.

• Publicly traded company with a mix of institutional and retail shareholders; significant holdings historically held by company founders and biotech-focused investment funds.
• Corporate governance includes a board with industry and financial expertise to oversee both diagnostics operations and non-core investment activities.

• To provide accessible, reliable molecular diagnostics that improve public health and clinical decision-making.
• Strategic emphasis on innovation in infectious disease, genetic disorder screening and oncology diagnostics while supporting long-term corporate stability through financial investments.

• Product sales: Core revenue from clinical test reagents, diagnostic instruments, kits and supporting consumables sold to hospitals, CDCs, third-party labs and distributors.
• Diagnostic coverage: Commercialized assays and systems for infectious diseases (e.g., respiratory viruses, HBV/HCV), genetic disorder screening (prenatal and newborn), and oncology-related molecular tests.
• Service & financial income: Revenue from after-sales services, calibration and training, plus income from investment activities and asset management operations that the company undertakes to diversify earnings.
• Geographic and channel mix: Sales via direct hospital/CDC contracts, regional distribution partners, and export markets-supporting recurring consumables demand alongside one-time instrument sales.

• R&D pipeline: Internal development of reagent chemistries and assay panels plus partnerships or licensing for platform technologies.
• Manufacturing & quality: In-house production lines for reagents and consumables under regulated quality systems to support clinical use and hospital procurement.
• Sales & distribution: Combination of direct sales teams for large institutional customers and distributor networks for wider regional penetration.
• Recurring-revenue engine: Consumable reagent kits and maintenance/service contracts create predictable repeat revenue after instrument placement.
• Financial diversification: Select investments and asset management activities provide non-operational income to smooth earnings variability from product cycles.

Daan Gene Co., Ltd. (002030.SZ): How It Makes Money

• Core product lines: molecular diagnostic kits (PCR/qPCR), reagents and consumables, diagnostic instruments and automation.
• Recurring revenue drivers: consumable kits and reagents sold to hospitals, CDCs, testing labs and third‑party distributors.
• Service & partnership income: instrument maintenance, OEM supply, and collaborative R&D / licensing agreements domestically and abroad.

• High-margin consumables: Many diagnostics companies earn most gross profit from repeat kit sales to existing installed instrument base.
• Instrument placement strategy: Selling instruments at competitive margins to build a recurring consumable ecosystem.
• R&D-driven product upgrades: New assays and higher‑throughput platforms support premium pricing and market share gains.
• Channel & scale: National distributor networks and public procurement (hospitals/CDC tenders) drive volume and pricing stability.

• Daan Gene is a leading player in China's molecular diagnostics market, with a material presence in PCR-based infectious disease and genetic screening segments.
• The company faces competition from both fast‑growing domestic biotech firms and established multinational IVD companies competing for hospital and public health contracts.
• Management has signaled expansion of product portfolio and diagnostic capabilities, with continued allocation of resources to R&D to capture evolving clinical and public health needs.
• Potential growth opportunities include deeper penetration of domestic hospital chains, expansion into international markets via distributors and licensing, and new product launches in NGS and automation.